[go: up one dir, main page]

ATE445639T1 - Globularer aufbau vom amyloid-beta- protein und deren verwendungen - Google Patents

Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Info

Publication number
ATE445639T1
ATE445639T1 AT04027742T AT04027742T ATE445639T1 AT E445639 T1 ATE445639 T1 AT E445639T1 AT 04027742 T AT04027742 T AT 04027742T AT 04027742 T AT04027742 T AT 04027742T AT E445639 T1 ATE445639 T1 AT E445639T1
Authority
AT
Austria
Prior art keywords
addls
activity
formation
amyloid beta
compounds
Prior art date
Application number
AT04027742T
Other languages
English (en)
Inventor
Grant A Kraft
William L Klein
Brett A Chromy
Mary P Lambert
Caleb E Finch
Todd Morgan
Pat Wals
Irina Rozovsky
Ann Barlow
Original Assignee
Univ Southern California
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23454671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445639(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Southern California, Univ Northwestern filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE445639T1 publication Critical patent/ATE445639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT04027742T 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen ATE445639T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36923699A 1999-08-04 1999-08-04

Publications (1)

Publication Number Publication Date
ATE445639T1 true ATE445639T1 (de) 2009-10-15

Family

ID=23454671

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00952571T ATE283285T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen
AT04027742T ATE445639T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00952571T ATE283285T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Country Status (9)

Country Link
EP (2) EP1571158B1 (de)
JP (1) JP4796725B2 (de)
AT (2) ATE283285T1 (de)
AU (1) AU6524500A (de)
CA (1) CA2381323C (de)
DE (2) DE60043165D1 (de)
ES (1) ES2235926T3 (de)
HK (1) HK1047944A1 (de)
WO (1) WO2001010900A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
MXPA02008145A (es) 2000-02-24 2004-04-05 Univ Washington Anticuerpos humanizados que secuestran al peptido beta amiloide.
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ES2391905T3 (es) 2001-08-17 2012-11-30 Washington University Método de ensayo para la enfermedad de alzheimer
EP1288226A1 (de) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modifizierung der Geneexpression der Mitglieder von "Toll"-ähnlicher Rezeptorfamilie zur Beeinflussung der Neurodegeneration und der Neuroprotektion im menschlichen Zentralnervensystem
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1535056A1 (de) * 2002-07-31 2005-06-01 Solvias AG Vorrichtung und messverfahren
AU2003279728B2 (en) * 2002-10-01 2007-09-27 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1596809B1 (de) 2003-02-10 2010-05-26 Applied Molecular Evolution, Inc. Abeta-bindende moleküle
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US8250823B2 (en) 2003-08-26 2012-08-28 Ejot Gmbh & Co. Kg Dowels and methods for the assembly of insulating panels
EP1755644A2 (de) * 2004-05-14 2007-02-28 Northwestern University Zubereitung enthaltend addlrezeptor syngap
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
MX2007010687A (es) 2005-03-05 2008-01-28 Abbott Gmbh & Co Kg Metodo de clasificacion, procedimiento para la purificacion de oligomeros a-beta no difundibles, anticuerpos selectivos contra dichos oligomeros a-beta no difundibles y un procedimiento para la fabricacion de dichos anticuerpos.
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
TW200726774A (en) * 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
MX2008006957A (es) 2005-11-30 2008-10-20 Abbott Lab Metodos para la preparacion de formas recombinantes de proteina beta-amiloide humana y usos de estas proteinas.
ES2527661T3 (es) 2005-11-30 2015-01-28 Abbvie Inc. Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
CA2630344C (en) 2006-03-23 2015-04-28 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR101414847B1 (ko) 2007-01-18 2014-07-03 일라이 릴리 앤드 캄파니 페길화된 Ａβ ＦＡＢ
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SI2448968T1 (sl) * 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
EP2368558A1 (de) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azoverbindungen zur Reduzierung der Bildung und der Toxizität von Amyloid-Beta-Aggregationszwischenprodukten
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
BR112014000671A2 (pt) 2011-07-13 2017-02-14 Merck Sharp & Dohme métodos para determinar o teor de uma proteína de interesse neuronalmente derivada, para determinar a eficácia terapêutica de um agente terapêutico para tratar mal de alzheimer, e, para determinar o acoplamento ao alvo de um anticorpo terapêutico ligado em uma proteína de interesse neuronalmente derivada
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
HUE053809T2 (hu) 2014-07-10 2021-07-28 Bioarctic Ab Javított A-béta protofibrillum-kötõ ellenanyagok
WO2019018445A1 (en) * 2017-07-17 2019-01-24 Maxwell Biosciences, Inc. POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES
WO2023107830A1 (en) * 2021-12-06 2023-06-15 The Board Of Trustees Of The Leland Stanford Junior University Amyloid oligomer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
AU748768B2 (en) * 1997-03-11 2002-06-13 General Hospital Corporation, The Identification of agents for use in the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
ES2235926T3 (es) 2005-07-16
HK1047944A1 (zh) 2003-03-14
WO2001010900A2 (en) 2001-02-15
EP1571158A3 (de) 2007-03-14
EP1571158A2 (de) 2005-09-07
EP1200470A2 (de) 2002-05-02
JP4796725B2 (ja) 2011-10-19
EP1571158B1 (de) 2009-10-14
CA2381323A1 (en) 2001-02-15
JP2003510023A (ja) 2003-03-18
CA2381323C (en) 2009-10-06
AU6524500A (en) 2001-03-05
WO2001010900A3 (en) 2001-08-30
DE60043165D1 (de) 2009-11-26
EP1200470B1 (de) 2004-11-24
DE60016227T2 (de) 2005-12-15
ATE283285T1 (de) 2004-12-15
DE60016227D1 (de) 2004-12-30

Similar Documents

Publication Publication Date Title
ATE283285T1 (de) Globularer aufbau vom amyloid-beta- protein und deren verwendungen
ATE349467T1 (de) Amyloid beta protein (globularer aufbau und seine verwendung)
WO2004031400A3 (en) Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
WO2003104437A3 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
WO1999015658A3 (en) Human regulatory molecules
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE362925T1 (de) Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2- familie exprimieren
KR890700666A (ko) 혈관 항응고 단백질, 이를 암호화하는 dna, 이의 제조방법 및 용도
ATE537186T1 (de) P53-bindendes polypeptid
WO2000012703A3 (en) Protein transport-associated molecules
WO2000052151A3 (en) Human secretory proteins
WO1999033870A3 (en) Human regulatory proteins
WO2000078953A3 (en) Human transport proteins
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
WO2001016317A3 (en) Polycyclic aromatic hydrocarbon induced molecules
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
WO2000071679A3 (en) Human oxidoreductase proteins
NO920524L (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse
WO2000078952A3 (en) Human rna metabolism proteins (rmep)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties